

해외 바이오의약품 임상 현황 ('23년 9월 3주)

한국바이오의약품협회, 2023.09.26.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.09.18.~2023.09.24.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 9건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05861050	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Biological: Glofitamab Drug: Lenalidomide Biological: Obinutuzumab Procedure: Positron Emission Tomography Drug: Venetoclax	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1 Phase 2	
NCT05954871	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Drug: GDC-1971 Drug: Osimertinib Drug: Cetuximab	Genentech, Inc.	Phase 1	
NCT05929768	Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Procedure: Biospecimen Collection Drug: Carboplatin Drug: Cyclophosphamide Drug: Docetaxel Drug: Doxorubicin Drug: Paclitaxel Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Questionnaire Administration Procedure: Surgical Procedure	SWOG Cancer Research Network National Cancer Institute (NCI)	Phase 3	
NCT05840770	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Procedure: Biospecimen Collection Biological: Cemiplimab Procedure: Computed Tomography Procedure: Magnetic Resonance Elastography Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	
NCT05854381	To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV	Biological: VIR-1388 Biological: Placebo	Vir Biotechnology, Inc. National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network	Phase 1	
NCT05822752	Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)	Drug: Budigalimab Drug: Livmoniplimab Drug: Lenvatinib Drug: Sorafenib	AbbVie	Phase 2	
NCT06006546	The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies	Biological: 426c.Mod.Core-C4b Other: Adjuvant 3M-052-AF+Alum	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	
NCT06040086	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations	Drug: Placebo Drug: Tozorakimab	AstraZeneca	Phase 3	
NCT05063565	TheraSphere With Durvalumab and Tremelimumab for HCC	Device: TheraSphere Y-90 glass microsphere therapy Drug: Durvalumab (Imfinzi) immunotherapy Drug: Tremelimumab immunotherapy	Boston Scientific Corporation Biocompatibles UK Ltd	Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 3주)

한국바이오의약품협회, 2023.09.26.

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	

○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	
NCT06040086	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations	Drug: Placebo Drug: Tozorakimab	AstraZeneca	Phase 3	

○ 중국 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05939167	Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage	Drug: mesenchymal stem cell Other: saline	Cell Energy Life Sciences Group Co. LTD Beijing 302 Hospital Shenzhen Third People's Hospital Fifth Hospital of Shijiazhuang City Beijing YouAn Hospital	Phase 1 Phase 2	
NCT06010953	SS109 and NovoSeven® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment	Drug: SS109	Jiangsu Gensciences Inc.	Phase 1 Phase 2	

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05822752	Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)	Drug: Budigalimab Drug: Livmoniplimab Drug: Lenvatinib Drug: Sorafenib	AbbVie	Phase 2	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	